Dongwha Pharm.Co.,Ltd Statistics
Total Valuation
Dongwha Pharm.Co.,Ltd has a market cap or net worth of KRW 174.35 billion. The enterprise value is 240.78 billion.
Market Cap | 174.35B |
Enterprise Value | 240.78B |
Important Dates
The next estimated earnings date is Friday, February 21, 2025.
Earnings Date | Feb 21, 2025 |
Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Dongwha Pharm.Co.,Ltd has 27.72 million shares outstanding. The number of shares has increased by 0.13% in one year.
Current Share Class | n/a |
Shares Outstanding | 27.72M |
Shares Change (YoY) | +0.13% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 13.42% |
Owned by Institutions (%) | 9.22% |
Float | 18.43M |
Valuation Ratios
The trailing PE ratio is 22.72.
PE Ratio | 22.72 |
Forward PE | n/a |
PS Ratio | 0.41 |
PB Ratio | 0.46 |
P/TBV Ratio | 0.60 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.78, with an EV/FCF ratio of -5.81.
EV / Earnings | 31.38 |
EV / Sales | 0.56 |
EV / EBITDA | 8.78 |
EV / EBIT | 26.63 |
EV / FCF | -5.81 |
Financial Position
The company has a current ratio of 2.02, with a Debt / Equity ratio of 0.19.
Current Ratio | 2.02 |
Quick Ratio | 1.15 |
Debt / Equity | 0.19 |
Debt / EBITDA | 2.80 |
Debt / FCF | -1.84 |
Interest Coverage | 5.35 |
Financial Efficiency
Return on equity (ROE) is 1.37% and return on invested capital (ROIC) is 1.25%.
Return on Equity (ROE) | 1.37% |
Return on Assets (ROA) | 1.03% |
Return on Capital (ROIC) | 1.25% |
Revenue Per Employee | 525.10M |
Profits Per Employee | 9.40M |
Employee Count | 816 |
Asset Turnover | 0.80 |
Inventory Turnover | 3.36 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.66% in the last 52 weeks. The beta is 1.06, so Dongwha Pharm.Co.,Ltd's price volatility has been similar to the market average.
Beta (5Y) | 1.06 |
52-Week Price Change | -35.66% |
50-Day Moving Average | 6,965.40 |
200-Day Moving Average | 8,062.40 |
Relative Strength Index (RSI) | 37.43 |
Average Volume (20 Days) | 54,972 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Dongwha Pharm.Co.,Ltd had revenue of KRW 428.48 billion and earned 7.67 billion in profits. Earnings per share was 276.85.
Revenue | 428.48B |
Gross Profit | 205.98B |
Operating Income | 8.89B |
Pretax Income | 9.82B |
Net Income | 7.67B |
EBITDA | 27.27B |
EBIT | 8.89B |
Earnings Per Share (EPS) | 276.85 |
Balance Sheet
The company has 40.09 billion in cash and 76.41 billion in debt, giving a net cash position of -36.32 billion or -1,310.33 per share.
Cash & Cash Equivalents | 40.09B |
Total Debt | 76.41B |
Net Cash | -36.32B |
Net Cash Per Share | -1,310.33 |
Equity (Book Value) | 405.92B |
Book Value Per Share | 13,558.23 |
Working Capital | 109.97B |
Cash Flow
In the last 12 months, operating cash flow was -8.95 billion and capital expenditures -32.49 billion, giving a free cash flow of -41.44 billion.
Operating Cash Flow | -8.95B |
Capital Expenditures | -32.49B |
Free Cash Flow | -41.44B |
FCF Per Share | -1,494.90 |
Margins
Gross margin is 48.07%, with operating and profit margins of 2.08% and 1.79%.
Gross Margin | 48.07% |
Operating Margin | 2.08% |
Pretax Margin | 2.29% |
Profit Margin | 1.79% |
EBITDA Margin | 6.36% |
EBIT Margin | 2.08% |
FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 180.00, which amounts to a dividend yield of 2.86%.
Dividend Per Share | 180.00 |
Dividend Yield | 2.86% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 65.03% |
Buyback Yield | -0.13% |
Shareholder Yield | 2.73% |
Earnings Yield | 4.40% |
FCF Yield | -23.77% |
Stock Splits
The last stock split was on June 30, 2009. It was a forward split with a ratio of 5.
Last Split Date | Jun 30, 2009 |
Split Type | Forward |
Split Ratio | 5 |
Scores
Dongwha Pharm.Co.,Ltd has an Altman Z-Score of 2.54. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.54 |
Piotroski F-Score | n/a |